Peramivir (Synonyms: 帕拉米韦; RWJ-270201; BCX-1812)

目录号: HY-17015A 纯度: 99.94%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Peramivir 是一种的新型环戊烷神经氨酸酶 (novel cyclopentane neuraminidase) 流感病毒抑制剂。Peramivir 具有抗病毒活性和抗细胞因子作用，可用于新型冠状病毒肺炎的研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Peramivir Chemical Structure

CAS No. : 330600-85-6

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
1 mg	￥285	In-stock
5 mg	￥640	In-stock
10 mg	￥1040	In-stock
25 mg	￥2000	In-stock
50 mg	￥3200	In-stock
100 mg	￥4480	In-stock
500 mg	现货	询价
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

Other Forms of Peramivir:

Peramivir trihydrate In-stock

MCE 顾客使用本产品发表的 10 篇科研文献

Peramivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 IKK 亚型特异性产品:

查看所有亚型

IKK-α IKK-β IKK IKKε TBK1

查看 JNK 亚型特异性产品:

查看所有亚型

JNK1 JNK2 JNK3 JNK

查看 STAT 亚型特异性产品:

查看所有亚型

STAT3 STAT5 STAT6 STAT1

查看 p38 MAPK 亚型特异性产品:

查看所有亚型

p38 MAPK p38α p38β MAPK13 p38δ p38γ

查看 ERK 亚型特异性产品:

查看所有亚型

ERK ERK1 ERK2 ERK5 ERK8

生物活性
纯度 & 产品资料
参考文献

生物活性

Peramivir is an novel cyclopentane neuraminidase inhibitor of influenza virus. Peramivir has antiviral activity and anti-cytokines stom effects. Peramivir can be used for the research of COVID-19^[1]^[2]^[3].

IC₅₀ & Target

IKK-α

STAT3

ERK1

ERK2

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	0.07 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad Inhibition of oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate ad	[PMID: 27167096]
HEK293	IC₅₀	0.3 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by sub	[PMID: 27167096]
HEK293	IC₅₀	0.7 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	[PMID: 27167096]
HEK293	IC₅₀	0.8 nM Compound: 5	Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure Inhibition of Influenza A virus A/Shanghai/01/2014(H7N9) recombinant wild type neuraminidase transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measure	[PMID: 27167096]
HEK293	IC₅₀	146 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase R292K mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	[PMID: 27167096]
HEK293	IC₅₀	225 nM Compound: 5	Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas Inhibition of Influenza A virus A/Brisbane/10/2007(H3N2) recombinant neuraminidase E119A mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition meas	[PMID: 27167096]
HEK293	IC₅₀	3.3 nM Compound: 5	Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by Inhibition of oseltamivir-resistant Influenza A virus A/Vietnam/1194/2004(H5N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by	[PMID: 27167096]
HEK293	IC₅₀	3.6 nM Compound: 5	Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft Inhibition of Influenza A virus A/WSN/1933(H1N1) recombinant neuraminidase H275Y mutant transfected in HEK293 cells using MUNANA as substrate assessed as release of 4-methylumbelliferone preincubated for 10 mins followed by substrate addition measured aft	[PMID: 27167096]
MDCK	CC₅₀	> 1 x 10⁵ nM Compound: 4; PE	Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter96 Aqueous non-radioactive cell proliferation assay	[PMID: 29324342]
MDCK	CC₅₀	> 1 x 10⁵ nM Compound: 5	Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Cytotoxicity against MDCK cells after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	CC₅₀	> 100 μM Compound: Peramivir	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 34700269]
MDCK	CC₅₀	> 200 μM Compound: Peramivir	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 31954881]
MDCK	IC₅₀	0.2 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	0.2 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Caledo	[PMID: 19651908]
MDCK	IC₅₀	0.28 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	0.3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12 Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring wild type neuraminidase infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam/12	[PMID: 19651908]
MDCK	IC₅₀	0.43 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.5 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Washington/01/2007 (H3N2)) measured in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.51 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	0.9 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	1 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase D198G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	1.47 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 1 with neuraminidase E119V mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	EC₅₀	1.5 nM Compound: 5	Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay Antiviral activity against oseltamivir-resistant Influenza A virus A/WSN/1933(H1N1) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by CellTiter 96 AQueous Non-Radioactive cell proliferation assay	[PMID: 27167096]
MDCK	IC₅₀	1.72 nM Compound: Peramivir	Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	142.4 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	213 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	[PMID: 19651908]
MDCK	IC₅₀	214.07 nM Compound: peramivir	Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against Influenza A virus (A/Texas/12/2007 (H3N2)) clone 2 with neuraminidase E119I mutant isolated from immunocompromized patient measured after X/CD4 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	IC₅₀	27 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	3 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam Antiviral activity against Influenza A virus (A/Vietnam/1203/2004 (H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus (A/Vietnam	[PMID: 19651908]
MDCK	IC₅₀	3 nM Compound: Peramivir	Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	3.51 nM Compound: Peramivir	Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	33.56 nM Compound: peramivir	Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay Antiviral activity against sInfluenza A virus (A/Texas/12/2007 (H3N2)) with neuraminidase E119(V/I) mutant isolated from immunocompromized patient measured after X/CD3 additional passages in MDCK cells by fluorescent NA inhibition assay	[PMID: 20194700]
MDCK	CC₅₀	373 μM Compound: 3	Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay Cytotoxicity against MDCK cells infected with Influenza A virus (A/WSN/33(H1N1)) after 72 hrs by CellTiter-Glo assay	[PMID: 29141777]
MDCK	IC₅₀	43.6 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase E119G mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	562.1 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222V and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	82.8 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus A/New Cal	[PMID: 19651908]
MDCK	IC₅₀	891.4 nM Compound: Peramivir	Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose Antiviral activity against Influenza A virus (A/Chicken/Laos/26/2006(H5N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose	[PMID: 19651908]
MDCK	IC₅₀	9.43 nM Compound: Peramivir	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of neuraminidase activity by fluorimetric assay	[PMID: 20713668]
MDCK	IC₅₀	95.5 nM Compound: Peramivir	Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus Antiviral activity against Influenza A virus A/New Caledonia/20/99 (H1N1)) harboring neuraminidase I222M and H274Y mutant infected in MDCK cells assessed as inhibition of viral-induced cytopathogenicity after 4 days post dose to IC50 for Influenza A virus	[PMID: 19651908]

体外研究
(In Vitro)

Peramivir (0.3125-40 μM, 4 h) 对巨噬细胞无毒性^[1]。
Peramivir (2-10 μM, 6-12 h) 抑制 LPS 诱导的 hPBMCs 细胞因子释放^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	RAW 264.7
Concentration:	0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:	4 h
Result:	Showed no apparent toxicity in the peramivir-treated macrophages at concentrations up to 40 μM.

体内研究
(In Vivo)

Peramivir (20-60 mg/kg，腹腔注射，单次剂量) 可抑制 LPS 诱导的细胞因子风暴，减轻急性肺损伤，延长细胞因子风暴综合征模型小鼠的生存时间^[1]。
Peramivir (75 mg/kg，肌肉注射，每天 1 次，连续 7 天) 在 B 型流感病毒感染的免疫抑制小鼠模型中拯救了 BR/08 致死性攻击的 BALB scid 小鼠^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cytokine storm syndrome model mice ^[1]
Dosage:	20 mg/kg, 60 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Decreased 8 cytokines including TNF-a, IFN-a, IFN-γ, chemokines (MCP-1), GM-CSF, IL-1β, IL-6 and IL-12. Showed less inflammatory cell infiltrations, mild alveolar thickening and less bleeding points or congestion. Showed significant protective effects to the lung tissues.

Animal Model:	Immunocompromised murine models of infuenza B virus infection^[2]
Dosage:	75 mg/kg
Administration:	Intramuscular injection (i.m.)
Result:	Conferred complete protection against lethality, whether it was administered in one (1×), two (2×), or four (4×) doses, with maximum mean weight loss of 10% to 14%. Resulted in a trend of decreasing virus replication in the nasal cavities and lungs. Reduced the virus titers and replication.

Clinical Trial

分子量

328.41

Formula

C₁₅H₂₈N₄O₄

CAS 号

330600-85-6

性状

固体

颜色

White to off-white

中文名称

帕拉米韦

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶解性数据

细胞实验：

1 M HCl 中的溶解度 : ≥ 100 mg/mL (304.50 mM)

DMSO 中的溶解度 : < 1 mg/mL (insoluble or slightly soluble)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.0450 mL	15.2249 mL	30.4497 mL
5 mM	0.6090 mL	3.0450 mL	6.0899 mL
10 mM	0.3045 mL	1.5225 mL	3.0450 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

计算结果

工作液所需浓度 : mg/mL

纯度 & 产品资料

纯度: 99.94%

选择批次：

Data Sheet (627 KB) SDS (393 KB)

COA (296 KB) HNMR (219 KB) RP-HPLC (247 KB) MS (68 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327. [Content Brief]

[2]. Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7(1): 7345. [Content Brief]

[3]. Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450. [Content Brief]

Peramivir 相关分类

Inflammation/Immunology Infection

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

1 M HCl	1 mM	3.0450 mL	15.2249 mL	30.4497 mL	76.1244 mL
	5 mM	0.6090 mL	3.0450 mL	6.0899 mL	15.2249 mL
	10 mM	0.3045 mL	1.5225 mL	3.0450 mL	7.6124 mL
	15 mM	0.2030 mL	1.0150 mL	2.0300 mL	5.0750 mL
	20 mM	0.1522 mL	0.7612 mL	1.5225 mL	3.8062 mL
	25 mM	0.1218 mL	0.6090 mL	1.2180 mL	3.0450 mL
	30 mM	0.1015 mL	0.5075 mL	1.0150 mL	2.5375 mL
	40 mM	0.0761 mL	0.3806 mL	0.7612 mL	1.9031 mL
	50 mM	0.0609 mL	0.3045 mL	0.6090 mL	1.5225 mL
	60 mM	0.0507 mL	0.2537 mL	0.5075 mL	1.2687 mL
	80 mM	0.0381 mL	0.1903 mL	0.3806 mL	0.9516 mL
	100 mM	0.0304 mL	0.1522 mL	0.3045 mL	0.7612 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Peramivir (Synonyms: 帕拉米韦; RWJ-270201; BCX-1812)

Customer Review

Other Forms of Peramivir:

MCE 顾客使用本产品发表的 10 篇科研文献

Peramivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 IKK 亚型特异性产品:

查看 JNK 亚型特异性产品:

查看 STAT 亚型特异性产品:

查看 p38 MAPK 亚型特异性产品:

查看 ERK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Peramivir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Peramivir (Synonyms: 帕拉米韦; RWJ-270201; BCX-1812)

Customer Review

Other Forms of Peramivir:

Peramivir 相关抗体

MCE 顾客使用本产品发表的 10 篇科研文献

Peramivir 相关产品

•相关化合物库:

•同靶点产品:

•同靶点蛋白产品:

查看 IKK 亚型特异性产品:

查看 JNK 亚型特异性产品:

查看 STAT 亚型特异性产品:

查看 p38 MAPK 亚型特异性产品:

查看 ERK 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Peramivir 相关抗体:

摩尔计算器

稀释计算器

Peramivir 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z